Share on Facebook Share on Twitter Email
Answers.com

Olivopontocerebellar atrophy

 
Neurological Disorder:

Olivopontocerebellar atrophy

Definition

Olivopontocerebellar atrophy (OPCA) is a group of disorders characterized by degeneration of three brain areas: the inferior olives, the pons, and the cerebellum. OPCA causes increasingly severe ataxia (loss of coordination) as well as other symptoms.

Description

Two distinct groups of diseases are called OPCA, leading to some confusion. Non-inherited OPCA, also called sporadic OPCA, is now considered a form of multiple system atrophy (MSA). Hereditary OPCA, also called inherited OPCA and familial OPCA, is caused by inheritance of a defective gene, which is recognized in some forms but not in others.

Demographics

Hereditary OPCA affects approximately 10,000 people in the United States, with males affected approximately twice as often as females. The average age of onset is 28 years.

Causes and symptoms

By definition, hereditary OPCA is caused by the inheritance of a defective gene. Several genes have been identified. The two most common are known as SCA-1 and SCA-2 (SCA stands for spinocerebellar ataxia). These genes cause similar, though not identical, diseases. Besides these two genes, there are at least 20 other genetic forms of the disease. For reasons that are not understood, these gene defects cause degeneration (cell death) in specific parts of the brain, leading to the symptoms of the disorder. The cerebellum is a principal center for coordination, and its degeneration leads to loss of coordination.

The most common early symptom of OPCA is ataxia, or incoordination, which may be observed in an unsteady gait or over-reaching for an object with the hand. Other common symptoms include dysarthria (speech difficulty), dysphagia (swallowing difficulty), nystagmus (eye tremor), and abnormal movements such as jerking, twisting, or writhing. Symptoms worsen over time.

Diagnosis

An initial diagnosis of OPCA can be made with a careful neurological examination (testing of reflexes, balance, coordination, etc.), plus a magnetic resonance image (MRI) of the brain to look for atrophy (loss of tissue) in the characteristic brain regions. Genetic tests exist for SCA-1 and SCA-2 forms. Many other types of tests are possible, although they are usually done only to rule out other conditions with similar symptoms or to confirm the diagnosis in uncertain cases. Because the symptoms of OPCA can be so variable, especially at the beginning of the disease, it may be difficult to obtain a definite diagnosis early on.

Treatment team

The treatment team is likely to consist of a neurologist, physical therapist, occupational therapist, speech/language pathologist, genetic counselor, and nursing care specialist.

Treatment

There are no treatments that reverse or delay the progression of OPCA.

Very few medications have any beneficial effect on OPCA symptoms. In some patients, Levodopa, also prescribed for Parkinson's disease, may initially help. Some anti-tremor medications, including propranolol, may also slightly help. Acetazolamide may be useful in some forms of the disease.

Treatment of OPCA is primarily directed toward reducing the danger of ataxia, and minimizing the impact of the disease on activities of daily living. Falling is the major danger early in the disease, and assistive mobile devices such as walkers and wheelchairs are often essential to prevent falling.

As the disease progresses, swallowing difficulties present the greatest danger. Softer foods and smaller mouthfuls are recommended. A speech-language pathologist can help devise swallowing strategies to lessen the risk of choking, and can offer advice on assisted communication as well. Late in the disease, a feeding tube may be needed to maintain adequate nutrition.

Prognosis

The life expectancy after diagnosis is approximately 15 years, although this is an average and cannot be used to predict the lifespan of any individual person.

Special concerns

Because OPCA is an inherited disease with identified genetic causes, it is reasonable to have other family members tested for the genes to determine if they, too, are at risk. This information may help family members to make personal decisions about their future, including decisions about family planning.

Resources

WEBSITES

National Ataxia Foundation. (April 19, 2004). http://www.ataxia.org.

National Organization for Rare Disorders. (April 19, 2004). http://www.rarediseases.org


Richard Robinson


Search unanswered questions...
Enter a question here...
Search: All sources Community Q&A Reference topics
Medical Dictionary: olivopontocerebellar atrophy
Top

n.

A progressive neurologic disease marked by loss of neurons in the cerebellar cortex, the pons, and the olivary nucleus.

Wikipedia: Olivopontocerebellar atrophy
Top
Olivopontocerebellar atrophy
Classification and external resources

Sagittal section through right cerebellar hemisphere. The right olive has also been cut sagitally.
ICD-10 G23.8[1]
ICD-9 333.0
DiseasesDB 2012 9208
MedlinePlus 000758
eMedicine neuro/282
MeSH D009849

Olivopontocerebellar atrophy (OPCA) is a term used to define neuronal degeneration in the cerebellum, pontine nuclei, and inferior olivary nucleus. The use of the term has changed considerably in recent years due to the progressing knowledge of the genetic basis of the disease.

The term was originally coined by Joseph Jules Dejerine and André Thomas.[2][3]

Contents

Current uses of the term

The term "olivopontocerebellar atrophy" currently applies only to two hereditary disorders whose genetic basis remains unknown:

Number OMIM Alt. name Inheritance
OPCA type 2 258300 Fickler[4]-Winkler[5] type OPCA autosomal recessive
OPCA type 5 164700 OPCA with dementia and extrapyramidal signs autosomal dominant

Obsolete uses of the term

In the past, the term "olivopontocerebellar atrophy" extended to both the sporadic (non-hereditary) cases of the disease, which have been currently reclassified as a form of multiple system atrophy[6], as well as to four hereditary types, which have been currently reclassified as four different forms of spinocerebellar ataxia:

Hereditary OPCA type OPCA name SCA # Gene OMIM
OPCA type 1 "Menzel type OPCA" SCA1 ATXN1 164400
OPCA type 2, autosomal dominant "Holguin type OPCA" SCA2 ATXN2 183090
OPCA type 3 "OPCA with retinal degeneration" SCA7 ATXN7 164500
OPCA type 4 "Schut-Haymaker type OPCA" SCA1 ATXN1 164400

References

  1. ^ http://www.nzhis.govt.nz/publications/newsletters/coders36.pdf
  2. ^ synd/1903 at Who Named It? - "Dejerine-Thomas atrophy"
  3. ^ J. J. Dejerine, A. Thomas. L’atrophie olivo-ponto-cérébelleuse. Nouvelle iconographie de la Salpêtrière, Paris, 1900, 13: 330-370. 1912, 25: 223-250.
  4. ^ Fickler, A. Klinische und pathologisch-anatomische Beitraege zu den Erkrankungen des Kleinhirns. Dtsch. Z. Nervenheilk. 41: 306-375, 1911.
  5. ^ Winkler, C. A case of olivo-pontine cerebellar atrophy and our conceptions of neo- and palaio-cerebellum. Schweiz. Arch. Neurol. Psychiat. 13: 684-702, 1923.
  6. ^ MeSH Result

External links


 
 

 

Copyrights:

Neurological Disorder. Gale Encyclopedia of Neurological Disorders. Copyright © 2005 by The Gale Group, Inc. All rights reserved.  Read more
Medical Dictionary. The American Heritage® Stedman's Medical Dictionary Copyright © 2002, 2001, 1995 by Houghton Mifflin Company Read more
Wikipedia. This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article "Olivopontocerebellar atrophy" Read more